Creative Planning
ACAD icon

Creative Planning’s Acadia Pharmaceuticals ACAD Stock Holding History

Creative Planning’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,000
Closed -$18K – 3751
2014
Q1 		$18K Buy
+4,000
New +$101K ﹤0.01% 2432

Other funds holding ACAD

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Creative Planning's ACAD Position: Q3 2026 in Review

Creative Planning increased its Acadia Pharmaceuticals (ACAD) stake by 25% in Q3 2026, buying an estimated $299K and bringing the position to 55,006 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2669.

Creative Planning first reported a position in ACAD in Q2 2013 and has held it in 48 quarters since. The position peaked at $2.18M in Q4 2017. 137 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Creative Planning held 55,006 shares of Acadia Pharmaceuticals worth $1.11M as of Q3 2026.
  • Creative Planning bought 11,144 Acadia Pharmaceuticals shares in Q3 2026, an estimated $299K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q3 2026, its #2669 holding.
  • Creative Planning first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
  • Creative Planning's Acadia Pharmaceuticals position peaked at $2.18M in Q4 2017.
  • 137 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Creative Planning's 13F filing for Q3 2026, filed 2 Nov 2026.